发明名称 Sonochemical induction of ABCA1 expression and compositions therefor
摘要 The present invention provides compositions useful for transfecting cells (e.g., liver cells) to express ABCA1. The compositions described herein comprise a pharmaceutically acceptable aqueous carrier containing sonochemically-active microspheres together with a plasmid DNA construct encoding an active form of ABCA1 and at least one promoter for the expression thereof. Preferably, the sonochemically-active microspheres comprise, consist essentially of, or consist of gas bubbles (e.g., a fluorocarbon gas, such as octafluoropropane) encapsulated within protein-containing or lipid-containing shells (e.g., human serum albumin shells). The microspheres are disruptable by exposure to ultrasonic acoustic energy to release the encapsulated gas.
申请公布号 US9101745(B2) 申请公布日期 2015.08.11
申请号 US201313826066 申请日期 2013.03.14
申请人 SONOGENE LLC 发明人 Coles Eric;Davidson Michael
分类号 A61M37/00;A61K31/7088;A61K45/06;A61K49/22;A61K41/00;A61K48/00;A61K31/713;C12N15/00 主分类号 A61M37/00
代理机构 Olson & Cepuritis, Ltd. 代理人 Olson & Cepuritis, Ltd.
主权项 1. A pharmaceutical composition for increasing HDL-cholesterol levels in the blood of a patient, the composition comprising a mixture of a nucleic acid encoding an expressible open reading frame and sonochemically-active microspheres in a pharmaceutically acceptable aqueous carrier; wherein the nucleic acid of the mixture consists of a plasmid vector, the expressible open reading frame consists of an expressible open reading frame encoding the active form of ATP-binding cassette transporter A1 (ABCA1), and the plasmid vector also includes at least one sequence adapted to promote expression of the open reading frame in a mammalian cell; and wherein the sonochemically-active microspheres comprise gas bubbles encapsulated within shells comprising a protein, a lipid, or a combination thereof, the microspheres being disruptable upon exposure to ultrasonic acoustic energy to release the encapsulated gas bubbles; and wherein the composition transfects liver cells when intravenously administered to the patient while ultrasonically imaging the liver, to elicit production of an increased level of HDL-cholesterol in the blood of the patient compared to the HDL-cholesterol level in the blood of the patient prior to administering the composition.
地址 Glen Ellyn IL US